Underweight AMGN: Trim 35-45% into strength zone; redefine $435 as breakout add-back trigger
The 35-45% trim magnitude synthesizes the aggressive analyst's 25-40% (too light given macro overhang) and conservative analyst's 50-70% (overcorrects given accelerating fundamentals); the residual 55-65% preserves meaningful exposure to macro defensive-rotation thesis and $8.65B FCF while bounding binary CPI tail risk; redefine $435 as breakout add-back trigger rather than protective stop; use conditional reentry (RSI <55, momentum reset, price confirmation) rather than pre-committed MA levels; maintain dividend exposure on residual core.
| Position | Action |
|---|---|
| Current price in $404-$414 strength zone | Trim 35-45% of AMGN exposure |
| Residual position on 5-8% gap down to $388-$394 post-CPI | Accept 12-15% drawdown on trimmed shares vs. 18-23% on full position |
| AMGN/SPY ratio breakdown on delayed/partial underweight execution | Fire trim trigger as explicit signal |
| Post-CPI close above $435 on volume >4M shares | Add back to full weight as breakout confirmation |
AMGN is a quality compounder in early-stage post-breakout mode, combining accelerating top-line growth, record margins, rapid deleveraging, strong free cash flow, defensive characteristics, and a confirmed technical breakout that makes any CPI-related dip an buying opportunity.
| Indicator | Value | Signal |
|---|---|---|
| close_200_sma | 344.62 | bullish |
| close_50_sma | 365.15 | bullish |
| close_10_ema | 400.75 | bullish |
| rsi | 71.50 | neutral |
| macd | 13.78 | bullish |
| macds | 10.80 | bullish |
| macdh | +2.98 | bullish |
| boll_ub | 421.26 | neutral |
| boll | 384.70 | bullish |
| boll_lb | 348.14 | neutral |
| atr | 11.64 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: MACD histogram stable, hold above prior breakout level $376
Then: Conditional reentry
Exiting the obesity program was capital discipline that freed resources for higher-return opportunities, not a strategic failure.
↩ rebuts: “Bear framing obesity exit as structural disadvantage”
· concedes: Obesity drug development is a massive market opportunity that AMGN has chosen not to pursue directly; Biosimilar pressure on legacy biologics is real and ongoing; AMGN's $43.3B net debt is a legitimate structural consideration; A hot CPI print (≥3.5% YoY) would pressure equities broadly near-term
AMGN is a quality company trading at an overpriced level—the stock sits 11.4% above fair value, the technical setup shows a 56% rally into overbought territory near the 52-week high, and the growth narrative conflates seasonal Q2 rebounds with structural inflection while abandoning the most valuable opportunity in pharma.
EV: -$42 downside to fair value ($372) · concedes: AMGN is a quality compounder; Q2 2026 was a clean earnings beat; Operating margin expansion did occur year-over-year
→ vs conservative: Quality at any price is not investing discipline; AMGN trades at 11.4% premium to fair value with PEG of 2.19, and holding through a 56% move without trimming is complacency, not conviction
→ vs neutral: Waiting for CPI is redundant because the market has already priced in the probabilities (86% zero Fed cuts, 72% hot CPI, modal CPI 3.3-3.4%); waiting produces no informational advantage and risks selling into weakness or chasing after the move
| vwma | ~391.44 | bullish |
Support: 348.14 · 376 | Resistance: 421.26
AMGN exhibits a high-confluence bullish breakout with trend, momentum, and volume aligned positively. All moving averages confirm the uptrend (price > 10 EMA > 50 SMA > 200 SMA), MACD confirms expanding bullish momentum, and VWMA's +14% rise validates institutional participation. RSI at 71.50 flags near-term overbought risk with price pressing the upper Bollinger Band (421.26). Recommended action is HOLD for existing positions with trailing stops in the $380-$395 region; fresh entries should await pullbacks to the 10 EMA (~400) or 50 SMA (~365) for better risk/reward. Invalidation below 376 on expanding volume would weaken the breakout thesis.
Market Cap
$224.14B
Share Price (52w High)
$421.79
Share Price (52w Low)
$269.77
50-Day Average
$363.60
200-Day Average
$346.93
PE (TTM)
25.73
Forward PE
17.11
PEG Ratio
2.19
Price/Book
19.16
EPS (TTM)
$16.10
Forward EPS
$24.22
Dividend Yield
2.42%
Beta
0.413
Shares Outstanding
541M
Revenue (Q2 2026)
$10,054M
Gross Profit (Q2 2026)
$7,243M
Gross Margin (Q2 2026)
72.0%
R&D Expense (Q2 2026)
$1,868M
SG&A (Q2 2026)
$1,745M
Operating Income (Q2 2026)
$3,514M
Operating Margin (Q2 2026)
35.0%
EBITDA (Q2 2026)
$4,553M
Net Income (Q2 2026)
$2,375M
Diluted EPS (Q2 2026)
$4.37
Tax Rate (Q2 2026)
14.2%
Cash & Equivalents (Q2 2026)
$13,989M
Receivables (Q2 2026)
$10,227M
Inventory (Q2 2026)
$6,220M
Goodwill & Intangibles (Q2 2026)
$39,155M
Total Assets (Q2 2026)
$95,639M
Total Debt (Q2 2026)
$57,304M
Net Debt (Q2 2026)
$43,315M
Stockholders' Equity (Q2 2026)
$11,688M
Current Ratio (Q2 2026)
1.37
Working Capital (Q2 2026)
$9,459M
Operating Cash Flow (Q2 2026)
$4,002M
CapEx (Q2 2026)
$513M
Free Cash Flow (Q2 2026)
$3,489M
Cash Dividends Paid (Q2 2026)
$1,362M
TTM Free Cash Flow
$8.65B
Gross Margin (TTM)
71.9%
Operating Margin (TTM)
35.5%
Net Profit Margin (TTM)
22.95%
EBITDA Margin (TTM)
45.3%
Return on Equity (TTM)
91.5%
Return on Assets (TTM)
8.67%
Revenue (TTM)
$38.09B
Net Income (TTM)
$8.74B
EBITDA (TTM)
$17.27B
Operating ROIC
17%
Strengths
Concerns
Amgen delivered strong Q2 2026 results with record revenue of $10.05B (+9.5% YoY), 72% gross margins, and 35% operating margins driven by biologics mix and operating leverage, while EPS surged 65% YoY to $4.37. The balance sheet shows meaningful improvement with cash up 74% YoY to $14B, net debt reduced $4.9B to $43.3B, and stockholders' equity up 57%, while the company generates exceptional free cash flow ($3.49B in Q2 alone). With a forward PE of 17.1x, ~50% expected EPS growth, defensive profile (beta 0.41), and 2.42% dividend yield, Amgen is fairly valued near 52-week highs but presents a BUY opportunity on pullbacks toward the 50-DMA (~$364).
Macro: The Fed is on hold with an 86% probability of no rate cuts in 2026, removing any near-term rate-cut tailwind for healthcare growth valuations. US inflation is running at a modal 3.3-3.4% YoY with a 72% probability of a +0.1% monthly print for July 2026, still firmly above the 2% target and representing re-inflation risk into tomorrow's Aug 12 CPI release. A soft-landing scenario remains the base case with only an 8% recession probability by end-2026. Geopolitically, oil prices are climbing on US-Iran deal doubts, with Strait of Hormuz risk premium rising again, creating a risk-off tone into the CPI print. The dominant binary catalyst for the week is tomorrow's CPI release.